Home > Boards > US Listed > Biotechs >

Champions Oncology, Inc. (CSBR)

Add CSBR Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/29/2019 8:44:17 AM - Followers: 41 - Board type: Free - Posts Today: 0


Edgar Filings:

2200 Wilson Blvd, Suite 102-316, Arlington, VA 22201

Primary State of Incorporation: Delaware

James Martell, Chairman/President/CEO
James E. McCollam, Secretary

On February 14, 2007, the Registrant agreed to acquire all of the patent rights underlying pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled “Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.” The acquisition represents the commencement of the Registrant’s strategy to develop a biotechnology business based on therapeutic drug candidates among other possible ventures.

The purchase price for the patent rights consisted of an aggregate of up to 550,000 restricted shares of common stock, of which 300,000 restricted shares were issued upon execution of the acquisition agreement and 250,000 restricted shares are issuable upon the issuance of one or patents based on U.S. Patent Application no. 11/673,519. The Registrant has 27,624,658 issued and outstanding common shares and of those, 19,573,000 are restricted common shares.

On January 5, 2007, the Registrant agreed to issue 7,000,000 shares of common stock toDr. David Sidransky, an individual investor, for an aggregate purchase price of $28,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.

On January 3, 2007, the Registrant agreed to issue 2,500,000 shares of common stock to Dr. Manuel Hidalgo, an individual investor, for an aggregate purchase price of $10,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.

David Sidransky, M.D.

David Sidransky, M.D., has served as a director of the ImClone Systems, since January 2004. On June 15, 2005, Dr. Sidransky was named Vice Chairman of the Board of Directors. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. He is a founder of several private biotechnology companies and has served on scientific advisory boards of many private and publicly traded companies, including MedImmune Inc., Telik Inc., Roche, and Amgen Inc. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the Board of Scientific Counselors at the National Institute of Dental and Craniofacial Research and a member of the Recombinant DNA Advisory Committee at the National Institute of Health. Dr. Sidransky serves on numerous editorial boards and is Senior Editor of Clinical Cancer Research. In addition, he is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award

Link to David Sidransky's patents:

Manuel Hidalgo, M.D., Ph.D.

-Associate Professor of Oncology at the Johns Hopkins Institute.
-M.D.,University Navarra Medical School, Pamplona, Spain
-Ph.D., Infectious Diseases in Cancer, Univeristy Autonoma, Madrid, Spain
-Fellowship (Medical Oncology) University Hospital “12 de Octubre”, Madrid, Spain
-Research Fellow, University Hospital “ 12 de Octubre”, Madrid, Spain
-Clinical Research Fellow, Cancer Therapy and Research Center, San Antonio, TX
-Board Certification in Medical Oncology
-Clinical Interests: Stomach cancer, Colon and rectum cancers, Pancreas cancer, Biliary Tract cancer, Gallbladder cancer.

Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing the biological activity in tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo is the Principal Investigator in four new clinical studies started within the last year at the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.

Link to Manuel Hidalgo's patents:

OS: 31,624,658 issued and outstanding common shares
Restricted: 23,573,000
Float: 8,051,658

Transfer Agent: Integrity Stock Transfer, Las Vegas, NV 89120


News Items and Filings

Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader


BALTIMORE, Sept. 1 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

By maintaining the fundamental genotypic features of the original human tumor along with the stromal components, the Biomerk Tumorgraft preclinical platform enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers.

"We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization."

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.




Weekly Chart

Long Term Chart

Daily Chart

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CSBR News: Quarterly Report (10-q) 03/15/2022 01:19:11 PM
CSBR News: Current Report Filing (8-k) 03/15/2022 12:32:11 PM
CSBR News: Amended Statement of Ownership (sc 13g/a) 02/14/2022 05:59:06 AM
CSBR News: Champions Oncology-Fannin team up to develop therapeutics for tumors 01/20/2022 07:05:52 AM
CSBR News: Quarterly Report (10-q) 12/13/2021 12:01:34 PM
#2378   https://seekingalpha.com/instablog/47797823-melikemsmallstocks/5296806-pktx-life Rocketstockpix 04/29/19 08:44:17 AM
#2377   https://championsoncology.com/news/champions-oncology-reports-record-quarterly-r axelvento 10/25/18 07:44:44 AM
#2376   I hope today was not it. Drift cjm24 10/10/18 07:07:56 PM
#2375   CSBR watch what happenes next! TrendTrade2016 10/05/18 05:23:14 AM
#2374   $20 in the viewfinder axelvento 10/04/18 03:58:19 PM
#2373   SS- 200,000,000 shares authorized axelvento 10/03/18 01:04:11 AM
#2372   This is getting very interesting. I have said cjm24 09/28/18 06:59:44 PM
#2371   up 17.5 axelvento 09/28/18 03:29:32 PM
#2370   CSBR here we go to test 19.64 TrendTrade2016 09/28/18 12:52:39 PM
#2369   CSBR target reached...boom!! TrendTrade2016 09/27/18 11:36:40 AM
#2368   stock of the year my friend!!! TrendTrade2016 09/27/18 10:37:58 AM
#2367   my friend $15.68 boom axelvento 09/27/18 10:36:23 AM
#2366   CSBR have raised the next top to be TrendTrade2016 09/26/18 06:05:21 AM
#2365   CSBR 16.32 in sight TrendTrade2016 09/20/18 06:10:22 AM
#2364   AH $15.00! cjm24 09/19/18 06:34:34 PM
#2363   BOOOOMMMM$$$$$$$$ axelvento 09/19/18 03:22:41 PM
#2362   $20 imminent,,,,,, axelvento 09/19/18 02:41:11 PM
#2361   this is for real players..go back the one TrendTrade2016 09/19/18 12:42:26 PM
#2360   That's an honest mistake, or, buying a stock JacksBack 09/19/18 10:06:00 AM
#2359   CSBR stock of the year!! TrendTrade2016 09/19/18 09:55:09 AM
#2358   14.20 in sight!! TrendTrade2016 09/18/18 06:13:02 PM
#2357   great thing about this company is they are TrendTrade2016 09/18/18 06:12:23 PM
#2356   Yeah, crazy. Sold and added along the way. cjm24 09/18/18 05:16:33 PM
#2355   Wow. You held this long. That’s incredible. ?? TrendTrade2016 09/18/18 03:24:34 PM
#2354   First buy was at 0.07. 2007 cjm24 09/18/18 12:32:03 PM
#2353   Have you kept track of this one?! Crazy long hold. cjm24 09/18/18 12:29:20 PM
#2352   I Bought back higher than my sell. That’s TrendTrade2016 09/18/18 11:12:21 AM
#2351   $12 next month 20,,,,,,,, axelvento 09/18/18 10:10:02 AM
#2350   may have made a mistake. This is a TrendTrade2016 09/17/18 07:01:04 PM
#2349   CSBR ya gotta know when to hold long!!! TrendTrade2016 09/15/18 07:04:03 AM
#2348   Boom is right friend. CSBR is a amazing TrendTrade2016 09/14/18 10:37:51 AM
#2347   monster: a/s200M o/s11M axelvento 09/14/18 09:54:32 AM
#2346   bingo!!!!!!!!!! trend axelvento 09/14/18 09:48:16 AM
#2345   CSBR ready to tackle the 10.50!! Beauty!!! TrendTrade2016 07/26/18 06:08:27 AM
#2344   CSBR monster bio!!! Here comes 9 buckaroos!!! TrendTrade2016 07/19/18 09:59:39 AM
#2343   been in it about a year and a TrendTrade2016 06/23/18 09:45:57 AM
#2342   I finally jumped in a year or so brewpup 06/21/18 08:20:49 PM
#2341   CSBR an amazing little bio play!! TrendTrade2016 06/20/18 10:48:40 AM
#2340   CSBR this stock is getting the attention it deserves!!! TrendTrade2016 06/05/18 03:18:05 PM
#2339   Been holding CSBR for 1 year now...patience paying TrendTrade2016 06/04/18 04:18:37 PM
#2338   Cbsr was mentioned by Seeking Alpha.. When You're Knocked Brando1975 10/26/17 11:21:19 PM
#2337   There was a 1-12 RS back in 2015. cjm24 09/22/17 08:46:40 PM
#2336   I had some at .05 too... MWM 09/21/17 09:32:35 PM
#2335   Same here. Back in 2007 I believe, single cjm24 08/10/17 10:15:38 PM
#2334   A company with real earnings equals share value. MC2 Atlantis 08/10/17 05:53:05 PM
#2333   CSBR seems to be coming along here of MC2 Atlantis 08/03/17 05:31:14 PM
#2332   What do you guys think is cooking? Decent cjm24 01/12/17 06:45:11 AM
#2331   http://ih.advfn.com/p.php?pid=nmona&article=73022401 altruism 12/03/16 07:06:10 AM
#2330   Where?? Kev2128 12/03/16 06:44:09 AM
#2329   Nice news... altruism 11/29/16 04:53:12 PM
Consent Preferences